On-treatment clinical remission of severe asthma with real-world longer-term biologic use
In a real-world cohort of patients with SA with longer-term biologic treatment, almost one-half achieved on-treatment clinical remission. With at least 1 year of biologic therapy, clinical remission is a feasible treatment goal in SA.
Authors
- Njira Lucia Lugogo (ORCID: https://orcid.org/0000-0002-0235-7105)
- Donna Carstens
- Christopher S. Ambrose (ORCID: https://orcid.org/0000-0003-4175-7336)
- Arpan Patel (ORCID: https://orcid.org/0000-0003-2758-1274)
- Bradley E. Chipps (ORCID: https://orcid.org/0009-0000-7857-9225)
- Wenjiong Zhou
- Warner Carr (ORCID: https://orcid.org/0000-0002-6519-5860)
- Frank Trudo
Institutions
- University of Michigan (US)
- Consumer Healthcare Products Association (US)
- Capital Allergy and Respiratory Disease Center (US)
- California Allergy and Asthma Medical Group (US)
- AstraZeneca (Switzerland) (CH)
- AstraZeneca (Italy) (IT)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology Global
- Published
- 2024-10-31
- DOI
- https://doi.org/10.1016/j.jacig.2024.100365
- Citations
- 6
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.96
Funders
- AstraZeneca